Suppr超能文献

脑肾上腺脑白质营养不良静止期的临床和影像学过程。

Clinical and radiographic course of arrested cerebral adrenoleukodystrophy.

机构信息

From the Department of Neurology (E.J.M., P.L.M., R.S., F.S.E.) and Department of Radiology (P.A.C.), Division of Neuroradiology, Harvard Medical School, Massachusetts General Hospital, Boston; Department of Pediatrics (E.J.M.), Division of Child Neurology, Weill Cornell Medical College, New York-Presbyterian Hospital, NY; and Department of Pediatric Neurology (S.v.d.S., M.E.), Emma Children's Hospital, Amsterdam University Medical Center, the Netherlands.

出版信息

Neurology. 2020 Jun 16;94(24):e2499-e2507. doi: 10.1212/WNL.0000000000009626. Epub 2020 Jun 1.

Abstract

OBJECTIVE

To gain insight into the natural history of arrested cerebral adrenoleukodystrophy (CALD) by quantifying the change in Neurologic Function Score (NFS) and Loes Score (LS) over time in patients whose cerebral lesions spontaneously stopped progressing.

METHODS

We retrospectively reviewed a series of 22 patients with arrested CALD followed longitudinally over a median time of 2.4 years (0.7-17.0 years). Primary outcomes were change in radiographic disease burden (measured by LS) and clinical symptoms (measured by NFS) between patients who never developed a contrast-enhancing lesion (gadolinium enhancement (GdE)- subgroup) and those who did (GdE+ subgroup). Secondary analyses comparing patterns of neuroanatomic involvement and lesion number, and prevalence estimates, were performed.

RESULTS

Cerebral lesions were first detected at a median age of 23.3 years (8.0-67.6 years) with an initial LS of 4 (0.5-9). NFS was 0.5 (0-6). Overall change in NFS or LS per year did not differ between subgroups. No patients who remained GdE- converted to a progressive CALD phenotype. The presence of contrast enhancement was associated with disease progression ( = 0.559, < 0.001). Four patients (18.2%) underwent step-wise progression, followed by spontaneous resolution of contrast enhancement and rearrest of disease. Three patients (13.6%) converted to progressive CALD. Nineteen patients (86.4%) had arrested CALD at the most recent follow-up. The prevalence of arrested CALD is 12.4%.

CONCLUSION

Arrested CALD lesions can begin in childhood, and patients are often asymptomatic early in disease. The majority of patients remain stable. However, clinical and MRI surveillance is recommended because a minority of patients undergo step-wise progression or conversion to progressive CALD.

摘要

目的

通过量化自发停止进展的脑肾上腺脑白质营养不良(CALD)患者的神经功能评分(NFS)和 Loes 评分(LS)随时间的变化,深入了解其自然病史。

方法

我们回顾性分析了 22 例经长期随访(中位数时间为 2.4 年,范围为 0.7-17.0 年)的自发停止进展的 CALD 患者系列。主要结局指标是从未出现对比增强病变(钆增强(GdE)亚组)和出现对比增强病变(GdE+亚组)的患者之间,放射学疾病负担(LS 测量)和临床症状(NFS 测量)的变化。还进行了比较神经解剖学受累模式和病变数量的次要分析,并进行了患病率估计。

结果

脑病变最初在中位数年龄 23.3 岁(8.0-67.6 岁)时被发现,初始 LS 为 4(0.5-9)。NFS 为 0.5(0-6)。亚组之间,NFS 或 LS 每年的变化无差异。未发生 GdE-的患者转变为进展性 CALD 表型。对比增强的存在与疾病进展相关( = 0.559,<0.001)。4 例(18.2%)患者进行了逐步进展,随后对比增强自发消退,疾病再次停止。3 例(13.6%)患者转为进展性 CALD。19 例(86.4%)患者在最近的随访中仍患有 CALD。CALD 停止进展的患病率为 12.4%。

结论

CALD 病变可始于儿童期,且患者在疾病早期通常无症状。大多数患者保持稳定。然而,建议进行临床和 MRI 监测,因为少数患者会发生逐步进展或转为进展性 CALD。

相似文献

1
Clinical and radiographic course of arrested cerebral adrenoleukodystrophy.
Neurology. 2020 Jun 16;94(24):e2499-e2507. doi: 10.1212/WNL.0000000000009626. Epub 2020 Jun 1.
2
Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant. 2019 Mar;25(3):538-548. doi: 10.1016/j.bbmt.2018.09.036. Epub 2018 Oct 4.
5
Five men with arresting and relapsing cerebral adrenoleukodystrophy.
J Neurol. 2021 Mar;268(3):936-940. doi: 10.1007/s00415-020-10225-7. Epub 2020 Sep 29.
6
Antioxidant Capacity and Superoxide Dismutase Activity in Adrenoleukodystrophy.
JAMA Neurol. 2017 May 1;74(5):519-524. doi: 10.1001/jamaneurol.2016.5715.
8
Volume of Gadolinium Enhancement and Successful Repair of the Blood-Brain Barrier in Cerebral Adrenoleukodystrophy.
Biol Blood Marrow Transplant. 2020 Oct;26(10):1894-1899. doi: 10.1016/j.bbmt.2020.06.019. Epub 2020 Jun 26.
9
MRI brain lesions in asymptomatic boys with X-linked adrenoleukodystrophy.
Neurology. 2019 Apr 9;92(15):e1698-e1708. doi: 10.1212/WNL.0000000000007294. Epub 2019 Mar 22.
10
Hypoperfusion predicts lesion progression in cerebral X-linked adrenoleukodystrophy.
Brain. 2012 Sep;135(Pt 9):2676-83. doi: 10.1093/brain/aws206.

引用本文的文献

1
Safety and efficacy of leriglitazone in childhood cerebral adrenoleukodystrophy (NEXUS): an interim analysis of an open-label, phase 2/3 trial.
EClinicalMedicine. 2025 May 24;84:103265. doi: 10.1016/j.eclinm.2025.103265. eCollection 2025 Jun.
2
Development of a rabbit model for adrenoleukodystrophy: A pilot study on gene therapy using rAAV9.
Mol Ther Nucleic Acids. 2025 Feb 3;36(1):102469. doi: 10.1016/j.omtn.2025.102469. eCollection 2025 Mar 11.
3
Current Advances and Challenges in Gene Therapies for Neurologic Disorders: A Review for the Clinician.
Neurol Genet. 2025 Jan 13;11(1):e200229. doi: 10.1212/NXG.0000000000200229. eCollection 2025 Feb.
4
Experiences of mothers of long-term surviving patients with cerebral adrenoleukodystrophy: a qualitative study.
Orphanet J Rare Dis. 2024 Oct 28;19(1):401. doi: 10.1186/s13023-024-03424-2.
6
Neurofilament light chain levels in cerebrospinal fluid as a sensitive biomarker for cerebral adrenoleukodystrophy.
Ann Clin Transl Neurol. 2023 Jul;10(7):1230-1238. doi: 10.1002/acn3.51818. Epub 2023 May 31.
7
Newborn screening for X-linked adrenoleukodystrophy in Italy: Diagnostic algorithm and disease monitoring.
Front Neurol. 2023 Jan 9;13:1072256. doi: 10.3389/fneur.2022.1072256. eCollection 2022.
9
Neurocognitive and mental health impact of adrenoleukodystrophy across the lifespan: Insights for the era of newborn screening.
J Inherit Metab Dis. 2023 Mar;46(2):174-193. doi: 10.1002/jimd.12581. Epub 2022 Dec 26.
10
International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy: A Consensus-Based Approach.
Neurology. 2022 Nov 22;99(21):940-951. doi: 10.1212/WNL.0000000000201374. Epub 2022 Sep 29.

本文引用的文献

1
Pearls & Oy-sters: Adolescent-onset adrenomyeloneuropathy and arrested cerebral adrenoleukodystrophy.
Neurology. 2019 Jul 9;93(2):81-84. doi: 10.1212/WNL.0000000000007755.
2
MRI brain lesions in asymptomatic boys with X-linked adrenoleukodystrophy.
Neurology. 2019 Apr 9;92(15):e1698-e1708. doi: 10.1212/WNL.0000000000007294. Epub 2019 Mar 22.
3
4
Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant. 2019 Mar;25(3):538-548. doi: 10.1016/j.bbmt.2018.09.036. Epub 2018 Oct 4.
5
Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies.
Blood Adv. 2018 Jan 4;2(1):49-60. doi: 10.1182/bloodadvances.2017010645. eCollection 2018 Jan 9.
8
Newborn screening for X-linked adrenoleukodystrophy in New York State: diagnostic protocol, surveillance protocol and treatment guidelines.
Mol Genet Metab. 2015 Apr;114(4):599-603. doi: 10.1016/j.ymgme.2015.02.002. Epub 2015 Feb 12.
9
Hematopoietic cell transplantation does not prevent myelopathy in X-linked adrenoleukodystrophy: a retrospective study.
J Inherit Metab Dis. 2015 Mar;38(2):359-61. doi: 10.1007/s10545-014-9797-1. Epub 2014 Dec 9.
10
Hematopoietic stem cell transplantation-50 years of evolution and future perspectives.
Rambam Maimonides Med J. 2014 Oct 29;5(4):e0028. doi: 10.5041/RMMJ.10162. eCollection 2014 Oct.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验